Alchemia: First granting of antibody patents
Key patent granted in Japan
The patent, JP 2000-593339, entitled “A composition and method for the enhancement of the efficacy of drugs” is the most recent grant in the family of patents protecting Alchemia’s HyACT® technology. Similar protection has already been granted in Australia, New Zealand, Canada, China, Taiwan and a number of European countries including Austria, Belgium, Denmark, France, Germany, Italy, Ireland, Luxembourg, Netherlands, Spain, Switzerland, and the United Kingdom.
“We are very pleased to secure IP protection for the important Japanese market where Irinotecan is widely used in the treatment of colorectal cancer. This patent family is integral in protecting the use of the HyACT® platform in conjunction with small molecule anticancer agents,” said Alchemia CEO Dr Pete Smith.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous